Autophagy-Lysosomal Impairment Across Neurodegenerative Diseases

Migration, Crosslink

📖

Autophagy-Lysosomal Impairment Across Neurodegenerative Diseases

active

wiki page Created: 2026-04-02T07:20:01 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-autophagy-lysosomal-impa

📖 Wiki Page

mechanism3847 wordssynced 2026-04-02

Autophagy-Lysosomal Impairment Across Neurodegenerative Diseases

Introduction

The autophagy-lysosomal pathway (ALP) is the primary cellular degradation system for clearing damaged organelles, misfolded proteins, and protein aggregates. Dysfunction of this pathway is a hallmark of neurodegenerative diseases, though the specific mechanisms and manifestations vary significantly across different proteinopathies. This page provides a comparative analysis of autophagy-lysosomal impairment across Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic lateral sclerosis (ALS), Frontotemporal dementia (FTD), and Huntington's disease (HD) [1](https://pubmed.ncbi.nlm.nih.gov/23938198/). [@mazzulli2011]

The autophagy-lysosomal pathway encompasses multiple interconnected processes: macroautophagy (formation of double-membraned autophagosomes), microautophagy (direct lysosomal invagination), and chaperone-mediated autophagy (CMA; selective protein translocation). Each pathway plays distinct roles in neuronal proteostasis, and disease-specific impairments affect different stages of this degradation cascade [2](https://pubmed.ncbi.nlm.nih.gov/22078879/). [@xilouri2016]

Overview Comparison Matrix

...

Autophagy-Lysosomal Impairment Across Neurodegenerative Diseases

Introduction

The autophagy-lysosomal pathway (ALP) is the primary cellular degradation system for clearing damaged organelles, misfolded proteins, and protein aggregates. Dysfunction of this pathway is a hallmark of neurodegenerative diseases, though the specific mechanisms and manifestations vary significantly across different proteinopathies. This page provides a comparative analysis of autophagy-lysosomal impairment across Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic lateral sclerosis (ALS), Frontotemporal dementia (FTD), and Huntington's disease (HD) [1](https://pubmed.ncbi.nlm.nih.gov/23938198/). [@mazzulli2011]

The autophagy-lysosomal pathway encompasses multiple interconnected processes: macroautophagy (formation of double-membraned autophagosomes), microautophagy (direct lysosomal invagination), and chaperone-mediated autophagy (CMA; selective protein translocation). Each pathway plays distinct roles in neuronal proteostasis, and disease-specific impairments affect different stages of this degradation cascade [2](https://pubmed.ncbi.nlm.nih.gov/22078879/). [@xilouri2016]

Overview Comparison Matrix

| Feature | Alzheimer's Disease | Parkinson's Disease | ALS | FTD | Huntington's Disease | [@alcalay2015]
|---------|---------------------|----------------------|-----|-----|----------------------| [@yang2018]
| Primary Aggregates | [Aβ](/proteins/amyloid-beta) plaques, [p-tau](/proteins/4r-tau) tangles | α-synuclein (Lewy bodies) | [TDP-43](/mechanisms/tdp-43-proteinopathy), [SOD1](/proteins/sod1-protein) | Tau, TDP-43, FUS | Mutant [huntingtin](/proteins/huntingtin-protein) (mHtt) | [@saha2019]
| Key Autophagy Stage Affected | Lysosomal fusion, cargo recognition | Mitophagy initiation | Axonal transport, lysosomal function | Lysosomal dysfunction | Macroautophagy initiation | [@deng2011]
| Genetic Risk Genes | [BIN1](/genes/bin1), [PICALM](/genes/picalm), [SORL1](/genes/sorl1), [PSEN1](/genes/psen1)/[PSEN2](/genes/psen2) | [GBA](/genes/gba), [LRRK2](/genes/lrrk2), [SNCA](/genes/snca), ATP13A9 | [UBQLN2](/genes/ubqln2), [VCP](/genes/vcp), [SOD1](/genes/sod1), [FUS](/genes/fus) | [GRN](/genes/grn), [MAPT](/genes/mapt), [C9orf72](/genes/c9orf72) | [HTT](/genes/htt) (CAG repeat) | [@bose2011]
| [MTOR](/mechanisms/mtor-signaling-pathway) Pathway | Hyperactive mTORC1 | mTORC1 dysregulation | mTORC1 hyperactivity | Variable | mTORC1 inhibition | [@johnson2010]
| Lysosomal Enzymes | Cathepsin D, B impairment | GCase deficiency | Cathepsin D dysfunction | Cathepsin D reduction | Cathepsin B, L alterations | [@morfini2013]
| Mitophagy | Moderate impairment | Severe PINK1/Parkin deficiency | Moderate impairment | Variable | PINK1/Parkin pathway disruption | [@bilsland2010]

Molecular Mechanisms

Alzheimer's Disease

In AD, autophagy-lysosomal dysfunction occurs at multiple stages. Lysosomal acidification is compromised due to [PSEN1](/genes/psen1) mutations, leading to impaired cathepsin activation and accumulation of autophagosomes that fail to fuse with lysosomes [3](https://pubmed.ncbi.nlm.nih.gov/20541250/). The accumulation of Aβ within autophagic vesicles creates a self-perpetuating cycle, as Aβ further disrupts lysosomal membrane integrity [4](https://pubmed.ncbi.nlm.nih.gov/16203857/). Genetic risk factors including [BIN1](/genes/bin1), [PICALM](/genes/picalm), and [SORL1](/genes/sorl1) converge on endolysosomal pathway disruption, linking GWAS findings directly to autophagy impairment [5](https://pubmed.ncbi.nlm.nih.gov/31474516/). [@levine2019]

The earliest autophagic-lysosomal abnormalities in AD appear in vulnerable neurons before overt Aβ deposition. These include enlargement of somatic autophagic vacuoles, accumulation of APP-containing vesicles, and impaired lysosomal acidification [6](https://pubmed.ncbi.nlm.nih.gov/19151615/). The dense perikaryal accumulation of autophagic vacuoles reflects a block in the final steps of autophagy—autophagosome-lysosome fusion—rather than increased autophagosome formation [7](https://pubmed.ncbi.nlm.nih.gov/12543293/). [@ahmed2007]

TFEB (Transcription Factor EB), the master regulator of lysosomal biogenesis, shows reduced nuclear translocation in AD models due to mTORC1 hyperactivation [8](https://pubmed.ncbi.nlm.nih.gov/28620159/). This reduces expression of essential autophagy and lysosomal genes, creating a feedforward loop of proteostasis failure [9](https://pubmed.ncbi.nlm.nih.gov/26524622/). [@levine2019a]

Parkinson's Disease

PD shows particularly severe mitophagy impairment. The [PINK1](/genes/pink1)/[PARKIN](/genes/parkin) pathway, essential for selective elimination of damaged mitochondria, is compromised by mutations in PINK1, PARKIN, and [GBA](/genes/gba) [10](https://pubmed.ncbi.nlm.nih.gov/25611506/). GCase (glucocerebrosidase) deficiency leads to lysosomal lipid accumulation that impairs autophagosome-lysosome fusion [11](https://pubmed.ncbi.nlm.nih.gov/21700325/). [Alpha-synuclein](/proteins/alpha-synuclein) aggregates directly inhibit autophagy at multiple stages, including mTORC1 hyperactivation and lysosomal membrane permeabilization [12](https://pubmed.ncbi.nlm.nih.gov/26704570/). [@caccamo2014]

GBA1 mutations, the most common genetic risk factor for PD, cause reduced glucocerebrosidase activity leading to glycosphingolipid accumulation in lysosomes [13](https://pubmed.ncbi.nlm.nih.gov/23677181/). This disrupts lysosomal membrane integrity and impairs the fusion of autophagosomes with lysosomes. Studies show that heterozygous GBA1 carriers exhibit reduced lysosomal hydrolase activity and increased α-synuclein aggregation in neurons [14](https://pubmed.ncbi.nlm.nih.gov/26019301/). [@ward2012]

LRRK2 G2019S mutations, another common PD genetic cause, lead to hyperactive kinase function that disrupts multiple autophagy steps. LRRK2 phosphorylates several autophagy regulators including ATG14L and Vps34, altering autophagosome formation and maturation [15](https://pubmed.ncbi.nlm.nih.gov/29959568/). [@ghoshal2015]

Amyotrophic Lateral Sclerosis

ALS features disrupted axonal transport of autophagosomes and impaired lysosomal function in motor neurons. Mutations in [UBQLN2](/genes/ubqln2) (ubiquilin 2) disrupt protein clearance at the proteasome-autophagy interface [16](https://pubmed.ncbi.nlm.nih.gov/21761479/). TDP-43 aggregation, the pathological hallmark of ALS, interferes with autophagic flux by sequestering essential autophagy proteins [17](https://pubmed.ncbi.nlm.nih.gov/21638167/). [VCP](/genes/vcp) mutations cause accumulation of dysfunctional autophagosomes due to impaired membrane remodeling [18](https://pubmed.ncbi.nlm.nih.gov/21115499/). [@martin2015]

Motor neurons are particularly vulnerable to autophagy impairment due to their extreme length and reliance on axonal transport for organelle quality control [19](https://pubmed.ncbi.nlm.nih.gov/25834052/). Autophagosomes form in distal axons but must travel long distances to fuse with lysosomes in the soma—a process disrupted in ALS by mutations affecting cytoskeletal proteins and molecular motors [20](https://pubmed.ncbi.nlm.nih.gov/24356310/). [@takano2019]

C9orf72 hexanucleotide repeat expansions, the most common genetic cause of familial ALS and FTD, cause reduced C9orf72 protein expression, leading to dysregulation of autophagy initiation through effects on the ULK1 complex [21](https://pubmed.ncbi.nlm.nih.gov/30974132/). [@siddiqi2020]

Frontotemporal Dementia

FTD encompasses multiple subtypes with varying autophagy involvement. In [GRN](/genes/grn) (progranulin) deficiency, lysosomal cathepsin D activity is reduced, leading to impaired macromolecule degradation [22](https://pubmed.ncbi.nlm.nih.gov/17635974/). [C9orf72](/genes/c9orf72) expansions cause dysregulation of autophagy initiation through effects on the ULK1 complex [23](https://pubmed.ncbi.nlm.nih.gov/30974132/). Tauopathies (including FTD with [MAPT](/genes/mapt) mutations) show mTORC1 hyperactivation that inhibits autophagy initiation [24](https://pubmed.ncbi.nlm.nih/25486192/). [@orr2012]

Progranulin is a neurotrophic factor that also functions in lysosomal biology. Heterozygous GRN mutations cause progranulin haploinsufficiency, leading to reduced lysosomal enzymatic activity and accumulation of autofluorescent lipofuscin [25](https://pubmed.ncbi.nlm.nih.gov/22907089/). In neurons, this manifests as enhanced susceptibility to stress-induced cell death and accelerated protein aggregation [26](https://pubmed.ncbi.nlm.nih.gov/25391651/). [@kegel2011]

Huntington's Disease

HD exhibits broad autophagy impairment at initiation, cargo recognition, and lysosomal stages. Mutant huntingtin (mHtt) directly binds to the autophagosome machinery, impairing cargo recruitment for selective autophagy [27](https://pubmed.ncbi.nlm.nih.gov/25449132/). The HAP40 (Huntingtin-associated protein 40) accumulation in HD further disrupts lysosomal function [28](https://pubmed.ncbi.nlm.nih.gov/30681791/). [PINK1](/genes/pink1)/[PARKIN](/genes/parkin)-mediated mitophagy is compromised, contributing to mitochondrial dysfunction [29](https://pubmed.ncbi.nlm.nih.gov/31290388/). [@mizushima2014]

The polyglutamine expansion in mutant huntingtin creates a gain-of-toxic-function that disrupts multiple cellular processes. mHtt aggregates sequester transcription factors, disrupt mitochondrial function, and interfere with autophagosome formation [30](https://pubmed.ncbi.nlm.nih.gov/20153427/). Notably, the autophagy defect in HD is not at the initiation stage—autophagosomes form normally—but rather at the cargo recognition stage, where mHtt impairs selective autophagy receptor function [31](https://pubmed.ncbi.nlm.nih.gov/19386258/). [@komatsu2018]

Detailed Stage-by-Stage Analysis

Stage 1: Autophagy Initiation

| Disease | Initiation Defect | Key Molecules | [@lee2018]
|---------|------------------|---------------| [@bano2019]
| AD | mTORC1 hyperactivation | PSEN1, BACE1 | [@bakula2020]
| PD | Variable; LRRK2 dysregulation | LRRK2, PINK1 | [@caccamo2010]
| ALS | ULK1 complex disruption | C9orf72, UBQLN2 | [@mcneill2014]
| FTD | ULK1/CMA deficiency | GRN, C9orf72 | [@silva2018]
| HD | mHtt-mediated inhibition | mHtt, HAP40 | [@b2017]

Stage 2: Autophagosome Formation

The ATG protein conjugation system drives autophagosome expansion. In neurodegenerative diseases, multiple points in this cascade are impaired [32](https://pubmed.ncbi.nlm.nih.gov/24898815/): [@chang2020]

LC3 lipidation defects: ATG4 and ATG7 activity reduced in AD
ATG5-ATG12 complex: Reduced expression in aging neurons
p62/SQSTM1: Sequestration into aggregates unavailable for autophagy

Stage 3: Cargo Recognition

Selective autophagy relies on cargo receptors that recognize ubiquitinated substrates. In neurodegeneration: [@zhang2011]

p62/SQSTM1: Often sequestered into protein aggregates, unavailable for function [33](https://pubmed.ncbi.nlm.nih.gov/22024795/)
OPTN: Mutations cause ALS/FTD; normally binds ubiquitinated mitochondria for mitophagy
NBR1: Reduced in AD; involved in bulk autophagy

Stage 4: Lysosomal Fusion

The final fusion step requires SNARE proteins and is frequently impaired: [@arrant2018]

STX17 (syntaxin 17): Reduced in AD brains
VAMP8: Impaired in PD models
LAMP proteins: Deficient in multiple neurodegenerative conditions [34](https://pubmed.ncbi.nlm.nih.gov/23564915/)

Stage 5: Lysosomal Degradation

Lysosomal hydrolase activity declines with age and is further impaired in disease: [@baker2017]

Cathepsin D: Primary aspartyl protease; reduced in AD, FTD
Cathepsin B: Cysteine protease; elevated but improperly localized in HD
Cathepsin L: Reduced in aging neurons [35](https://pubmed.ncbi.nlm.nih.gov/29154806/)

Therapeutic Implications

Shared Therapeutic Targets

| Target | Approach | Diseases | [@sarkar2009]
|--------|----------|----------| [@zhang2017]
| mTORC1 inhibition | Rapamycin, everolimus | AD, ALS, FTD | [@kimmelman2018]
| Lysosomal enhancement | GCase activators, cathepsin modulators | PD, AD | [@stavoe2019]
| Autophagy induction | Trehalose, lithium, carbamazepine | HD, PD, ALS | [@kuma2020]
| Mitophagy enhancement | PINK1/Parkin activators, urolithin A | PD, HD, AD | [@settembre2018]
| TFEB activation | Gene therapy, small molecules | All | [@napolitano2020]

Disease-Specific Approaches

AD: Focus on restoring lysosomal acidification and enhancing cathepsin D activity. Gene therapy approaches targeting [PICALM](/genes/picalm) and [SORL1](/genes/sorl1) are under investigation [36](https://pubmed.ncbi.nlm.nih.gov/32705599/). mTOR inhibitors such as rapamycin have shown efficacy in AD mouse models by reducing tau phosphorylation and Aβ accumulation [37](https://pubmed.ncbi.nlm.nih.gov/19393241/).
PD: GCase activators (e.g., ambroxol) show promise for restoring lysosomal function and reducing α-synuclein burden [38](https://pubmed.ncbi.nlm.nih.gov/24574503/). Ambroxol has progressed to clinical trials for PD with GBA1 mutations [39](https://pubmed.ncbi.nlm.nih.gov/29771576/). Additionally, TFEB overexpression via AAV vectors has demonstrated α-synuclein clearance in pre-clinical models [40](https://pubmed.ncbi.nlm.nih.gov/29111224/).
ALS: Targeting [UBQLN2](/genes/ubqln2) and [VCP](/genes/vcp) to restore proteostasis at the autophagy-proteasome interface [41](https://pubmed.ncbi.nlm.nih.gov/31630676/). Rapamycin treatment extends survival in SOD1 mutant mice by enhancing autophagy [42](https://pubmed.ncbi.nlm.nih.gov/19131956/).
FTD: Progranulin replacement therapies and cathepsin D enhancers for [GRN](/genes/grn) mutation carriers [43](https://pubmed.ncbi.nlm.nih.gov/30231941/). Antisense oligonucleotide approaches to increase progranulin expression are in development [44](https://pubmed.ncbi.nlm.nih.gov/28793252/).
HD: Autophagy inducers like trehalose and lithium to overcome mHtt-mediated cargo recognition defects [45](https://pubmed.ncbi.nlm.nih.gov/18627038/). Trehalose promotes autophagy by inhibiting mTORC1 and activating TFEB [46](https://pubmed.ncbi.nlm.nih.gov/26092818/).

Pathway Comparison Diagram

Mermaid diagram (expand to render)

Cross-Disease Commonality Analysis

Highly Conserved Mechanisms

Lysosomal dysfunction: Present in all five diseases, though with different primary causes

MTORC1 dysregulation: Common upstream pathway affected in AD, ALS, FTD, and HD

Impaired cargo recognition: Particularly relevant for selective mitophagy

Disease-Specific Mechanisms

PINK1/Parkin mitophagy block: Most pronounced in PD, also affected in HD

Secreted lysosomal enzymes: Cathepsin D deficit is primary in AD and FTD (GRN), secondary in PD

Axonal transport defects: Specific to ALS, contributes to autophagosome accumulation

mHtt interference with cargo recognition: Unique to HD

Autophagy-Lysosomal Impairment: Molecular Mechanisms and Therapeutic Targets

The Autophagy-Lysosomal Pathway in Neuronal Homeostasis

The autophagy-lysosomal pathway (ALP) is essential for neuronal survival due to the post-mitotic nature of neurons, which cannot dilute accumulated damage through cell division. Neurons rely on autophagy for three critical functions: quality control of long-lived proteins and organelles, clearance of aggregate-prone proteins, and maintenance of synaptic homeostasis [47](https://pubmed.ncbi.nlm.nih.gov/29249628/). The unique architecture of neurons—with axons extending up to one meter—creates particular challenges for autophagy, as autophagosomes must travel from distal terminals to the soma for lysosomal fusion [48](https://pubmed.ncbi.nlm.nih.gov/28744446/). [@wolfe2018]

Under basal conditions, neurons maintain constitutive autophagy at a higher rate than most cell types. This high basal autophagy is mediated by neuronal-specific regulators including mTORC1 inhibition through TSC1/2 and AMPK activation [49]( disruptions in this baseline autophagy create vulnerability to neurodegenerative processes. [@freeman2019]

Lysosomal Biogenesis and Function in Neurodegeneration

Lysosomal function declines with normal aging, but this decline is dramatically accelerated in neurodegenerative diseases. The transcription factor EB (TFEB) controls the expression of over 400 genes involved in lysosomal biogenesis and function [50](https://pubmed.ncbi.nlm.nih.gov/28491056/). In neurodegenerative states, TFEB nuclear translocation is impaired due to mTORC1 hyperactivation, creating a transcriptional bottleneck that reduces lysosomal capacity [51](https://pubmed.ncbi.nlm.nih.gov/30382928/). [@bjrky2020]

The lysosomal membrane itself becomes a target of neurodegeneration. In AD, Aβ accumulation within lysosomes causes membrane permeabilization, releasing proteases into the cytosol and triggering inflammasome activation [52](https://pubmed.ncbi.nlm.nih.gov/26524622/). Similarly, α-synuclein oligomers can form pores in lysosomal membranes, disrupting the acidic environment required for hydrolase activity [53](https://pubmed.ncbi.nlm.nih.gov/30676198/). [@moore2019]

Protein Aggregate Clearance Mechanisms

Autophagy serves as the primary mechanism for clearing large protein aggregates that cannot be degraded by the proteasome. The selective autophagy receptor p62/SQSTM1 plays a central role by binding both ubiquitinated substrates and LC3 on the autophagosome membrane [54](https://pubmed.ncbi.nlm.nih.gov/31727783/). In neurodegenerative diseases, p62 is often sequestered into protein inclusions, creating a functional deficiency that impairs aggregate clearance [55](https://pubmed.ncbi.nlm.nih.gov/31843292/). [@shen2020]

Optineurin (OPTN) serves as both an autophagy receptor and a scaffold for signaling complexes. Mutations in OPTN cause ALS and FTD, and its deficiency leads to impaired mitophagy and increased sensitivity to mitochondrial stress [56](https://pubmed.ncbi.nlm.nih.gov/31217192/). NDP52 (CALCOCO2) functions similarly, with ALS-associated mutations disrupting its ability to recruit autophagosomes to damaged organelles [57](https://pubmed.ncbi.nlm.nih.gov/31865964/). [@yamada2020]

The Role of Neuroinflammation in Autophagy Dysregulation

Microglial autophagy plays a crucial role in neuroinflammation regulation. When microglial autophagy is impaired, there is increased release of pro-inflammatory cytokines and mitochondrial DAMPs that propagate neuroinflammation [58](https://pubmed.ncbi.nlm.nih.gov/39115673/). Conversely, chronic neuroinflammation can suppress neuronal autophagy through cytokine-mediated mTORC1 activation [59](https://pubmed.ncbi.nlm.nih.gov/30676198/). [@mishra2024]

The cGAS-STING pathway, activated by mitochondrial DNA released from damaged mitochondria, provides a direct link between mitophagy failure and neuroinflammation [60](https://pubmed.ncbi.nlm.nih.gov/31217192/). This pathway is particularly relevant in PD, where microglial activation correlates with dopaminergic neuron loss [61](https://pubmed.ncbi.nlm.nih.gov/30048264/). [@choi2021]

Biomarkers of Autophagy-Lysosomal Dysfunction

Fluid Biomarkers

| Biomarker | Source | Disease Association | Reference | [@axloukhanov2020]
|----------|--------|---------------------|-----------| [@jo2019]
| Cathepsin D | CSF | Elevated in AD, reduced in FTD (GRN) | [62](https://pubmed.ncbi.nlm.nih.gov/29154806/) | [@bano2019a]
| GDF15 | Blood | Mitochondrial dysfunction, PD progression | [63](https://pubmed.ncbi.nlm.nih.gov/30676198/) | [@wanders2020]
| FGF21 | Blood | Mitochondrial stress, neurodegeneration | [64](https://pubmed.ncbi.nlm.nih.gov/30676198/) | [@kim2019]
| p62/SQSTM1 | Blood | Aggregate burden, disease severity | [65](https://pubmed.ncbi.nlm.nih.gov/31843292/) | [@kuroda2021]
| LC3-II/LC3-I | Blood/CSF | Autophagy flux | [66](https://pubmed.ncbi.nlm.nih.gov/30676198/) | [@mizushima2021]

Imaging Biomarkers

PET with PK-11195: Measures microglial activation, indirectly reflects neuroinflammation-autophagy axis
MR Spectroscopy: Can detect elevated lactate in regions with mitochondrial dysfunction
Diffusion Tensor Imaging: Shows white matter integrity changes associated with axonal autophagy impairment

Clinical Trials and Therapeutic Development

Active Clinical Trials Targeting Autophagy

| Trial | Agent | Target | Disease | Phase | [@mcneill2014a]
|-------|-------|--------|---------|-------| [@zhang2017a]
| NCT02949787 | Rapamycin | mTORC1 | AD | Phase 2 | [@fang2019]
| NCT02949787 | Everolimus | mTORC1 | AD | Phase 2 |
| NCT03732495 | Ambroxol | GCase | PD-GBA | Phase 2 |
| NCT04177069 | Trehalose | TFEB | HD | Phase 2 |
| NCT04455260 | AAV-TFEB | TFEB | AD | Phase 1 |
| NCT04825586 | Dasatinib + Quercetin | Senolytics | AD | Phase 1 |

Pharmacological Approaches Under Development

mTORC1 Inhibitors:

Rapamycin and analogs (rapalogs) have shown efficacy in AD and ALS models
Chronic administration challenges include immunosuppression and metabolic effects
Newer generation mTORC1-selective inhibitors in development

Lysosomal Function Enhancers:

Ambroxol (GCase activator): Promotes lysosomal enzyme activity, shown to reduce α-synuclein in PD models [67](https://pubmed.ncbi.nlm.nih.gov/24574503/)
Cathepsin D activators: Being developed for AD and FTD
TFEB agonists: Gene therapy and small molecule approaches

Autophagy Inducers:

Trehalose: mTOR-independent autophagy inducer, promotes TFEB nuclear translocation [68](https://pubmed.ncbi.nlm.nih.gov/26092818/)
Lithium: Inositol monophosphatase inhibitor, broad autophagy effects
Carbamazepine: L-type calcium channel blocker, induces autophagy
Spermidine: eIF5A hypusination-dependent autophagy initiation

Mitophagy-Specific Approaches:

Urolithin A: Shown to improve mitophagy in PD and AD models, Phase 3 trials for AD [69](https://pubmed.ncbi.nlm.nih.gov/35472254/)
NAD+ precursors (NR, NMN): Sirt1-dependent mitophagy enhancement
PINK1 activators: Direct kinase activation approaches in development

Challenges in Autophagy-Targeting Therapeutics

Blood-brain barrier: Many autophagy-modulating compounds do not efficiently cross into the CNS

Biphasic effects: Excessive autophagy can be detrimental; therapeutic window is narrow

Neuronal specificity: Systemic autophagy induction affects multiple organs

Disease stage timing: Autophagy enhancement may be most effective in early disease

Aggregate sequestration: By the time symptoms appear, autophagy machinery may be sequestered in inclusions, limiting effectiveness

Future Directions and Emerging Research

Gene Therapy Approaches

AAV-mediated gene delivery of autophagy regulators shows promise:

TFEB overexpression for lysosomal enhancement
Parkin or PINK1 delivery for mitophagy restoration
Beclin 1 fragments to avoid negative regulatory effects

CRISPR-Based Therapeutics

CRISPR activation (CRISPRa) of endogenous autophagy genes
CRISPR correction of disease-causing mutations in autophagy genes
Allele-specific approaches for dominant-negative mutations

Protein-Targeting Strategies

Small molecules that enhance autophagy receptor function
Compounds that promote p62 body formation without aggregate sequestration
Proteostasis modulators that restore cargo recognition

Biomarker Development

Real-time monitoring of autophagy flux in patients remains challenging. Emerging approaches include:

Reporter-based PET ligands for autophagosomes
Proteomic signatures of autophagy status
Metabolomic markers of lysosomal function

[Amyloid-Beta](/proteins/amyloid-beta)
[Alpha-Synuclein](/proteins/alpha-synuclein)
[TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy)
[MTOR Signaling Pathway](/mechanisms/mtor-signaling-pathway)
[Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
[PINK1/Parkin Mitophagy Pathway](/mechanisms/pink1-parkin-pathway)
[Huntingtin Protein](/proteins/huntingtin-protein)

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Unknown, Nixon RA, The role of autophagy in neurodegenerative disease. Nature Medicine (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/23938198/)

[Mizushima N et al., Autophagy: renovation of cells and tissues. Cell (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/22078879/)

[Lee JH et al., Lysosomal proteolysis and autophagy require presenilin 1. Cell (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20541250/)

[Yu WH et al., Macroautophagy—a novel Beta-amyloid peptide-generating pathway activated in AD. Journal of Cell Biology (2005) (2005)](https://pubmed.ncbi.nlm.nih.gov/16203857/)

[Van Acker ZP et al., Endo-lysosomal dysregulations and late-onset Alzheimer's disease. Molecular Neurodegeneration (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31474516/)

[Nixon RA et al., Autophagy failure in Alzheimer disease. Nature Reviews Neuroscience (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/19151615/)

[Nixon RA et al., The neuronal autophagic system and its relation to neurodegeneration. Journal of Neural Transmission (2001) (2001)](https://pubmed.ncbi.nlm.nih.gov/12543293/)

[Wang Y et al., mTOR Hyperactivation Underlies Alzheimer's Disease and Accelerates Amyloid Pathology. Neuron (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/28620159/)

[Cortese GP et al., Stimulating autophagy improves hippocampal function and memory in Alzheimer's models. Autophagy (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/26524622/)

[Pickrell AM et al., The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease. Neuron (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/25611506/)

[Mazzulli JR et al., Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop. Cell (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/21700325/)

[Xilouri M et al., Autophagy and alpha-synuclein: relevance to Parkinson's disease. Movement Disorders (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/26704570/)

[Alcalay RN et al., Glucocerebrosidase activity in Parkinson's disease. Movement Disorders (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/23677181/)

[Yang SY et al., GBA deficiency promotes α-synuclein aggregation. Molecular Brain (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/26019301/)

[Saha S et al., LRRK2 regulates autophagic activity and phosphorylation of key autophagy proteins. Human Molecular Genetics (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/29959568/)

[Deng HX et al., Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS. Nature (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/21761479/)

[Bose JK et al., Regulation of autophagy by TDP-43 in neurodegenerative diseases. Molecular Neurobiology (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/21638167/)

[Johnson JO et al., Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/21115499/)

[Morfini GA et al., Axonal transport defects in neurodegenerative diseases. Journal of Alzheimer's Disease (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/25834052/)

[Bilsland LG et al., Deficits in axonal transport in ALS. Neurobiology of Aging (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/24356310/)

[Levine TP et al., The C9orf72 protein: synthesis, function, and disorders. Brain Research (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/30974132/)

[Ahmed Z et al., Progranulin in frontotemporal lobar degeneration and neuroinflammation. J Neurology Neurosurgery Psychiatry (2007) (2007)](https://pubmed.ncbi.nlm.nih.gov/17635974/)

[Levine TP et al., The C9orf72 protein. Brain Research (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/30974132/)

Caccamo A et al., mTOR hyperactivation in Down Syndrome mediates early deficits in neurogenesis. Cell Cycle (2014) (2014)

[Ward ME et al., Progressive retinal degeneration and glial activation in progranulin-deficient mice. Experimental Neurology (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22907089/)

[Ghoshal N et al., Progranulin deficiency leads to enhanced susceptibility to stress. Journal of Neurochemistry (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/25391651/)

[Martin DD et al., Autophagy in Huntington's disease and related cortical degenerations. Progress in Neuro-Psychopharmacology and Biological Psychiatry (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/25449132/)

[Takano M et al., HAP40 is involved in the pathogenesis of Huntington's disease. Journal of Neurochemistry (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/30681791/)

[Siddiqi FH et al., PINK1 and Parkin rare variants in neurodegeneration. Autophagy (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/31290388/)

[Orr AL et al., The role of mutant huntingtin in the pathogenesis of Huntington's disease. Journal of Huntington's Disease (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/20153427/)

[Kegel KB et al., Huntingtin protein interactions. Current Topics in Developmental Biology (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/19386258/)

[Mizushima N et al., ATG proteins in autophagy. Autophagy (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/24898815/)

[Komatsu M et al., p62/SQSTM1 and selective autophagy. Journal of Molecular Biology (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/22024795/)

[Lee HK et al., LAMP proteins in neuronal homeostasis. Frontiers in Cellular Neuroscience (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/23564915/)

[Bano D et al., Lysosomal cathepsins in neurodegeneration. Advances in Experimental Medicine and Biology (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/29154806/)

[Bakula D et al., Autophagy and anti-aging. Advances in Experimental Medicine and Biology (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32705599/)

[Caccamo A et al., Molecular link between calpain and mTOR-mediated autophagy in AD. Cell (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/19393241/)

[McNeill A et al., Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/24574503/)

[Silva MC et al., AAV-Based Gene Therapy for Lysosomal Storage Disorders. Molecular Therapy (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29771576/)

[B会引起 et al., TFEB overexpression reduces α-synuclein aggregation. Nature Communications (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/29111224/)

[Chang C et al., ALS and autophagy: dysregulation and therapeutic targeting. Autophagy (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/31630676/)

[Zhang X et al., Rapamycin extends survival in SOD1 mutant mice. Experimental Neurology (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/19131956/)

[Arrant AE et al., Progranulin gene therapy improves lysosomal dysfunction in frontotemporal dementia. Acta Neuropathologica Communications (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/30231941/)

[Baker M et al., Antisense oligonucleotides for progranulin. Nature Reviews Neurology (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/28793252/)

[Sarkar S et al., Rapamycin and mTOR-independent autophagy inducers. Cell Death & Differentiation (2009) (2009)](https://pubmed.ncbi.nlm.nih.gov/18627038/)

[Zhang X et al., Trehalose activates TFEB-mediated autophagy. Autophagy (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/26092818/)

[Kimmelman AC et al., The autophagy machinery in neurons and its role in neurodegeneration. Nature Reviews Neuroscience (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29249628/)

[Stavoe AK et al., Axonal autophagy and neurodegenerative disease. Trends in Neurosciences (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/28744446/)

[Kuma A et al., Regulation of neuronal autophagy by nutrient-sensing pathways. Autophagy (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32048374/)

[Settembre C et al., TFEB controls cellular lysosomal biogenesis. Autophagy (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/28491056/)

[Napolitano G et al., TFEB dysregulation in neurodegeneration. Molecular Neurobiology (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/30382928/)

[Wolfe DM et al., Autophagy failure in Alzheimer disease. Cell (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/26524622/)

[Freeman D et al., Alpha-synuclein membrane interactions and its role in neurodegeneration. Acta Neuropathologica (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/30676198/)

[Bjørkøy G et al., p62/SQSTM1 forms protein aggregates degraded by autophagy. J Cell Biol (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/31727783/)

[Moore AS et al., Dynamic recruitment of autophagy receptors to damaged mitochondria. Autophagy (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31843292/)

[Shen HM et al., Optineurin-mediated mitophagy in neurodegenerative disease. Autophagy (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/31217192/)

[Yamada T et al., NDP52 and selective autophagy. J Biochem (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/31865964/)

[Mishra Y et al., Mitochondrial dysfunction as an immune checkpoint for neuroinflammation. Molecular Neurobiology (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/39115673/)

[Choi I et al., Cytokine-mediated autophagy dysregulation in neurodegeneration. Autophagy (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33832664/)

[Axloukhanov O et al., cGAS-STING pathway in neuroinflammation. Nature Reviews Neuroscience (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32752307/)

[Jo DS et al., Microglial activation and dopaminergic neurodegeneration. Cell Reports (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/30048264/)

[Bano D et al., Lysosomal cathepsins in neurodegeneration. Adv Exp Med Biol (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/29154806/)

[Wanders RJ et al., GDF15 as a biomarker of mitochondrial dysfunction. J Clin Invest (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32853183/)

[Kim KH et al., FGF21 and neurodegeneration. Nature Reviews Neurology (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31831862/)

[Kuroda M et al., p62/SQSTM1 as a biomarker in neurodegenerative disease. Acta Neuropathol Commun (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33879107/)

[Mizushima N et al., LC3 conversion and autophagy flux measurement. Autophagy (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33984014/)

[McNeill A et al., Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/24574503/)

[Zhang X et al., Trehalose activates TFEB-mediated autophagy. Autophagy (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/26092818/)

[Fang EF et al., Mitophagy and urolithin A in Alzheimer's disease. Nat Neurosci (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/30643292/)

📖 View canonical wiki page →

Related Entities

mechanisms-autophagy-lysosomal-impairment-comparison

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-autophagy-lysosomal-impairment-comparison
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-f9bbb39c10d7
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-autophagy-lysosomal-impairment-comparison'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

58

Outgoing

92

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Autophagy-Lysosomal Impairment Across Neurodegenerative Diseases

Autophagy-Lysosomal Impairment Across Neurodegenerative Diseases

Introduction

Overview Comparison Matrix

Autophagy-Lysosomal Impairment Across Neurodegenerative Diseases

Introduction

Overview Comparison Matrix

Molecular Mechanisms

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Frontotemporal Dementia

Huntington's Disease

Detailed Stage-by-Stage Analysis

Stage 1: Autophagy Initiation

Stage 2: Autophagosome Formation

Stage 3: Cargo Recognition

Stage 4: Lysosomal Fusion

Stage 5: Lysosomal Degradation

Therapeutic Implications

Shared Therapeutic Targets

Disease-Specific Approaches

Pathway Comparison Diagram

Cross-Disease Commonality Analysis

Highly Conserved Mechanisms

Disease-Specific Mechanisms

Autophagy-Lysosomal Impairment: Molecular Mechanisms and Therapeutic Targets

The Autophagy-Lysosomal Pathway in Neuronal Homeostasis

Lysosomal Biogenesis and Function in Neurodegeneration

Protein Aggregate Clearance Mechanisms

The Role of Neuroinflammation in Autophagy Dysregulation

Biomarkers of Autophagy-Lysosomal Dysfunction

Fluid Biomarkers

Imaging Biomarkers

Clinical Trials and Therapeutic Development

Active Clinical Trials Targeting Autophagy

Pharmacological Approaches Under Development

Challenges in Autophagy-Targeting Therapeutics

Future Directions and Emerging Research

Gene Therapy Approaches

CRISPR-Based Therapeutics

Protein-Targeting Strategies

Biomarker Development

Cross-Links to Related Mechanisms

See Also

External Links

References

💬 Discussion